Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results

Naeem Bhojani, Mohamed Bidair, Kevin C. Zorn, Andrew Trainer, Andrew Arther, Eugene Kramolowsky, Leo Doumanian, Dean Elterman, Ronald P. Kaufman, James Lingeman, Amy Krambeck, Gregg Eure, Gopal Badlani, Mark Plante, Edward Uchio, Greg Gin, Larry Goldenberg, Ryan Paterson, Alan So, Mitch HumphreysSteven Kaplan, Jay Motola, Mihir Desai, Claus Roehrborn

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

OBJECTIVE: To report 12-month safety and effectiveness outcomes of the Aquablation procedure for the treatment of men with symptomatic benign prostatic hyperplasia (BPH)and large-volume prostates. METHODS: One hundred and one men with moderate-to-severe BPH symptoms and prostate volumes of 80-150 cc underwent a robotic-assisted Aquablation procedure in a prospective multicenter international clinical trial. Functional and safety outcomes were assessed at 12 months postoperatively. RESULTS: Mean prostate volume was 107 cc (range 80-150). Mean operative time was 37 minutes and mean Aquablation resection time was 8 minutes. The average length of hospital stay following the procedure was 1.6 days. Mean International Prostate Symptom Score improved from 23.2 at baseline to 6.2 at 12 months (P <.0001). Mean International Prostate Symptom Score quality of life improved from 4.6 at baseline to 1.3 at 12-month follow-up (P <.0001). Significant improvements were seen in Qmax (12-month improvement of 12.5 cc/sec)and postvoid residual (drop of 171 cc in those with postvoid residual >100 at baseline). Antegrade ejaculation was maintained in 81% of sexually active men. No patient underwent a repeat procedure for BPH symptoms. There was a 2% de novo incontinence rate at 12 months, and 10 patients did require a transfusion postoperatively while 5 required take back fulgurations. At 12 months, prostate-specific antigen reduced from 7.1 ± 5.9 ng/mL at baseline to 4.4 ± 4.3 ng/mL. CONCLUSION: The Aquablation procedure is demonstrated to be safe and effective in treating men with large prostates (80-150 cc)after 1 year of follow-up, with an acceptable complication rate and without a significant increase in procedure or resection time compared to smaller sized glands. ClinicalTrials.gov number, NCT03123250.

Original languageEnglish (US)
JournalUrology
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results'. Together they form a unique fingerprint.

  • Cite this

    Bhojani, N., Bidair, M., Zorn, K. C., Trainer, A., Arther, A., Kramolowsky, E., Doumanian, L., Elterman, D., Kaufman, R. P., Lingeman, J., Krambeck, A., Eure, G., Badlani, G., Plante, M., Uchio, E., Gin, G., Goldenberg, L., Paterson, R., So, A., ... Roehrborn, C. (2019). Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results. Urology. https://doi.org/10.1016/j.urology.2019.04.029